Item 8.01 Other Events.

Alector, Inc. (the "Company"), in collaboration with AbbVie Biotechnology, Ltd. ("AbbVie"), has been developing AL003 to treat patients with Alzheimer's disease as one of two programs pursuant to the Co-Development and Option Agreement, dated as of October 16, 2017, between the parties (the "AbbVie Agreement"). AL003 focuses on modulating checkpoint receptors on the brain's immune cells, targeting sialic acid binding Ig-like lectin 3 (SIGLEC 3, also called CD33). As previously disclosed, the Company was reviewing the next steps for the AL003 program together with AbbVie. After completion of such review, AbbVie has decided to terminate the CD33 collaboration program and pursuant to the terms of the AbbVie Agreement, on June 30, 2022, AbbVie provided written notice to the Company formalizing this decision.

The Company, in collaboration with AbbVie pursuant to the AbbVie Agreement, continues to develop the Company's AL002 program, which is focused on targeting Triggering Receptor Expressed on Myeloid cells 2 (TREM2), for the treatment of Alzheimer's disease.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses